Alzheimers Association · Phase 2 Trial · 2026-05-14
PreliminaryDiranersen BIIB080, a tau-targeting therapy, misses primary endpoint in CELIA Phase 2
Why it matters. The Phase 2 trial did not meet its primary endpoint, though the sponsor reports encouraging tau reduction. Treat as hypothesis-generating pending confirmatory data.
Provenance
- Source
- Alzheimers Association
- Source type
- medical_society
- Content analyzed
- abstract
Evidence grading reflects the portion of the source actually analyzed. Always confirm against the original before acting.
Your read
Post your interpretation for colleagues. Every post stays anchored to this source, no empty-box updates.
Sign in to post your read of this evidence.